{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:22:04Z","timestamp":1768004524713,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jfo.2021.06.012","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:13:24Z","timestamp":1636672404000},"page":"1505-1515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of intravitreal injection of bevacizumab in treated and untreated eyes of Black African patients with polypoidal choroidal vasculopathy"],"prefix":"10.1016","volume":"44","author":[{"given":"N.N.","family":"Kabedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Kayembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Mwanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2021.06.012_bib0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0210","first-page":"1","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV), 1990","volume":"32","author":"Yannuzzi","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0215","first-page":"359","article-title":"Polypoidal choroidal vasculopathy: an update on therapeutic approaches","volume":"8","author":"Wong","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.jfo.2021.06.012_bib0220","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4103\/ijo.IJO_975_18","article-title":"Current management strategy of polypoidal choroidal vasculopathy","volume":"66","author":"Ho","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0225","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Koh","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0230","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2021.06.012_bib0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/tjo.tjo_35_18","article-title":"Polypoidal choroidal vasculopathy: an update on current management and review of literature","volume":"9","author":"Palkar","year":"2019","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0240","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","article-title":"One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy","volume":"31","author":"Cheng","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10384-019-00687-2","article-title":"Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting","volume":"63","author":"Gomi","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000175312","article-title":"Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy","volume":"223","author":"Song","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2021.06.012_bib0260","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10384-010-0813-1","article-title":"Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab","volume":"54","author":"Tsujikawa","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0265","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/IAE.0b013e31820d3f28","article-title":"Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up","volume":"31","author":"Bessho","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0275","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","article-title":"The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients","volume":"253","author":"Cheung","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12886-017-0631-z","article-title":"Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy","volume":"17","author":"Park","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/IAE.0b013e318198148e","article-title":"Intravitreal injection of 2.5mg versus 1.25mg bevacizumab (Avastin) for treatment of CNV associated with AMD","volume":"29","author":"Modarres","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2011.0023","article-title":"Intravitreal injection of 2.5mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up","volume":"27","author":"Chen","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2021.06.012_bib0295","first-page":"60","article-title":"Intravitreal bevacizumab injection for choroidal neovascularisation secondary to angioid streaks in pseudoxanthoma elasticum patients","volume":"4","author":"Kal","year":"2016","journal-title":"Adv Ophthalmol Vis Syst"},{"key":"10.1016\/j.jfo.2021.06.012_bib0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0305","first-page":"3352","article-title":"Efficacy of intravitreal bevacizumab (Avastin) for polypopidal choroidal vasculopathy","volume":"48","author":"Lew","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2021.06.012_bib0310","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1755-3768.2009.01841.x","article-title":"Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study","volume":"90","author":"Lim","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0315","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0301-4738.64130","article-title":"Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term results","volume":"58","author":"Mitamura","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0320","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0301-4738.109390","article-title":"Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy","volume":"61","author":"Chhablani","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3341\/kjo.2008.22.2.92","article-title":"The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy","volume":"22","author":"Lee","year":"2008","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0330","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3341\/kjo.2012.26.3.157","article-title":"Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"Cho","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0335","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0181-5512(08)75458-5","article-title":"Polypoidal choroidal vasculopathy: clinical and angiographic features","volume":"31","author":"Guyomarch","year":"2008","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0340","first-page":"4103871","article-title":"Polypoidal choroidal vasculopathy in congolese patients","author":"Kabedi","year":"2020","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0345","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/OPTH.S47511","article-title":"Pattern of presentation of idiopathic polypoidal choroidal vasculopathy in Ibadan, Sub-Saharan Africa","volume":"7","author":"Oluleye","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0350","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0355","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2021.06.012_bib0360","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2021.06.012_bib0365","first-page":"8561895","article-title":"Therapeutic effect of anti-vegf for age-related macular degeneration in the untreated fellow eye","volume":"2018","author":"Isildak","year":"2018","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.jfo.2021.06.012_bib0370","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/CIA.S93820","article-title":"Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration","volume":"11","author":"Michalska-Malecka","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jfo.2021.06.012_bib0375","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab","volume":"137","author":"Parikh","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0380","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/2474126419865990","article-title":"Fellow-eye conversion and treatment in exudative age-related macular degeneration","volume":"3","author":"Dow","year":"2019","journal-title":"J Vitreoretinal Dis"},{"key":"10.1016\/j.jfo.2021.06.012_bib0385","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"Miyake","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2021.06.012_bib0390","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1755-3768.2009.01842.x","article-title":"Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans","volume":"90","author":"Meyer","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0395","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials","volume":"149","author":"Barbazetto","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.06.012_bib0400","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2009.0126","article-title":"Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration","volume":"26","author":"Gamulescu","year":"2010","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221004824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221004824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:16:42Z","timestamp":1759259802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551221004824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0181551221004824"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2021.06.012","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of intravitreal injection of bevacizumab in treated and untreated eyes of Black African patients with polypoidal choroidal vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2021.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}